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A B S T R A C T
Objectives: Detection of activating epidermal growth factor receptor (EGFR) mutation is crucial for in-
dividualized treatment of advanced non-small-cell lung cancer (NSCLC). However little is known about how
biopsy technique affects the detection rate of EGFR mutations. This retrospective, single center study evaluated
the detection rate of EGFR mutations in tissue obtained by bronchoscopic cryobiopsy and compared this to other
standard tissue sampling techniques.
Materials and methods: We retrospectively analyzed 414 patients with histologically confirmed NSCLC and
known EGFR mutation status between 3/2008-7/2014. Tumor specimens obtained by tissue preserving
bronchoscopic cryobiopsy were compared to those obtained by other techniques.
Results and conclusion: Analysis of bronchoscopic cryobiopsy tissue detected 29 activating EGFR mutations in 27
(21.6 %) out of 125 patients, while analysis of tissue obtained by non-cryobiopsy techniques (bronchoscopic
forceps biopsies, fine needle aspiration, imaging guided transthoracical and surgical procedures) detected 42
EGFR mutations in 40 (13.8 %) out of 298 patients (p< 0.05). Cryobiopsy increased detection rate of EGFR
mutations in central tumors compared with forceps biopsy (19.6 % versus 6.5 %, p< 0.05), while an insig-
nificant trend was detected also for peripheral tumors (33.3 % versus 26.9 %).
Bronchosopic cryobiopsy increases the detection rate of activating EGFR mutations in NSCLC in comparison
to other tissue sampling techniques. This will help to optimize individualized treatment of patients with ad-
vanced tumors. Because of the retrospective nature of this analysis, a prospective trial is mandatory for final
assessment.
1. Introduction
Lung cancer ranks among the most common cancers worldwide with
approximately 1.8 million patients in 2012 [1,2]. Non small cell lung
cancer (NSCLC) represents 75–85 % of all lung cancers. 2/3 of these
patients are in non-curable stage III and IV at the time of diagnosis, and
are usually treated systemically [3]. The current management of non-
curable NSCLC has become more and more individualized and is based
on immunohistochemical and molecular tumor characterization [4]. In
this context, EGFR mutation is currently the most relevant molecular-
genetic alteration [5] since target therapies directed to activating EGFR
mutation not only have a much better side effect profile [6], but also
lead to an improved clinical response [7], an improved progression free
survival, and an improved overall survival in certain subgroups (e.g.
with deletion in Exon 19 [8–14]).
As a consequence, precise and correct molecular characterization of
advanced stage III and IV NSCLC is crucial for ensuring optimal treat-
ment, and missing any targetable alteration may result in suboptimal
therapy. Therefore, representative tumour tissue of adequate volume
and quality forms the basis for optimal histological and molecular
evaluation. EGFR testing lays the cornerstone for current NSCLC
treatment in advanced stages [15]. Apart from surgical resection and
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radiologically guided biopsies, the standard techniques to obtain tissue
samples in patients with suspected lung cancer are bronchoscopic for-
ceps biopsy and fine needle aspiration [16]. However, there has been no
detailed evaluation of the quality of biopsy specimen required for
molecular testing, nor has there been an evaluation as to which biopsy
technique provides the best material for molecular testing. As a result,
guidelines on molecular testing of NSCLC do not discuss the quality of
biopsy specimens required for EGFR testing, and limit their re-
commendations to statements like “a sufficient cancer cell content and
appropriate DNA quantity and quality” [17,18] are required. This had
led to the imprecise advice that each laboratory defines its own criteria
[17]. Even in prospective large multicentre trials evaluating the effect
of targeted therapies, criteria addressing the quality of biopsy speci-
mens needed for molecular testing are usually not specified [19].
The recently developed technique of cryobiopsy for the diagnosis of
patients with endobronchial tumor has revealed a significantly higher
diagnostic yield for lung cancer than conventional forceps biopsy [20].
In addition, cryobiopsy samples are of sufficiently large size to routinely
allow immunohistological staining [21]. Cryobiopsy provides better
tissue preservation without biopsy artifacts. Nevertheless, it cannot be
ruled out that physical alterations caused by the freezing and thawing
cycle during cryobiopsy could influence the diagnostic value on a mo-
lecular level.
We have therefore evaluated the detection rate of EGFR mutations
in cryobiopsies and compared these to other biopsy techniques in pa-
tients with pathologically proven non small cell lung cancer.
2. Patients and methods
2.1. Study design and population
This retrospective single center study was performed at the
Department of Internal Medicine II in collaboration with the Institute of
Pathology at the University of Tuebingen, Germany. All malignant
tissue samples from the University Hospital which had been examined
for EGFR mutations between March 2008 and July 2014 were included
in this study. A total of 483 tissue samples were analyzed for mutations
of the EGFR gene on exon 18, 19, 20, 21 using Sanger sequencing [22].
60 tumor samples were excluded because of extrapulmonary tumor
origin or unspecified diagnoses, and another 9 cases with cancer of
unknown primary were excluded (Fig. 1). Altogether 414 patients with
histologically confirmed NSCLC were included in the analysis. The
study protocol and the retrospective evaluation of the patient specific
data were approved by the ethics committee of the University of Tue-
bingen (Project number 466/2014BO1).
2.2. Sampling procedures and data source
In 125 cases (30.2 %) the tissue samples had been obtained by
cryobiopsy in the manner as previously described [21] using cryop-
robes of 1.9 or 2.4 mm diameter (Erbe Elektromedizin GmbH, Tue-
bingen, Germany) and a freezing time of up to 10 s depending on the
freezing power and diameter of the cryoprobes. In the remaining 289
cases (69.8 %), the “non-cryobiopsy” group, other diagnostic proce-
dures were performed (see Fig. 1). Of these, conventional broncho-
scopic forceps biopsy was undertaken in 98 cases (23.7 %). M.B., W.S.
and J.H. carried out all bronchoscopies, and type of biopsy (cryobiopsy,
forceps biopsy or fine needle aspiration) was decided by each in-
vestigator. More than 80 % of radiologically guided transthoracic
biopsies were performed by M.H., and by V.S. for surgical techniques.
Diagnostic video assisted thoracic surgery was predominately per-
formed for pleural resection (n = 12) showing pleural carcinosis and
for resection of a peripheral nodule (n = 5). Only in a single case video
assisted thoracoscopy was proceeded for lymph nodes extraction.
For both the cryobiopsy and non-cryobiopsy group specific patient
data included age, gender, and smoking history, as well as tumor
characteristics including localization, staging (according to the 7th lung
cancer TNM classification and staging system) [23] and histopatholo-
gical classification. Only those samples in which EGFR testing was
possible were included in the analysis. For all tissue specimens histo-
pathological diagnosis of NSCLC and EGFR mutation analysis were
performed on the same tissue sample. All histological and EGFR mu-
tation analyses were done at the Institute of Pathology at the University
of Tuebingen.
2.3. DNA extraction and EGFR mutation detection (Sanger Sequencing)
Genomic DNA was isolated from 5 μm paraffin-embedded tissue
sections, partially after macrodissection to enrich tumor cell content.
Tissue was dewaxed and digested with proteinase K for 16 h and DNA
was purified applying standard phenol/chloroform purification [24].
DNA was amplified for exon 18, 19, 20 and 21 of the EGFR gene using
M13-tailed primers previously published (exon 18, 21 [25] and 19, 20
[26]).
PCR was performed using 100 ng DNA template in a final volume of
50 μl with 0.2 μM of each primer, 0,2 mM dNTPs, 1.5 mM MgCl2 and
one Unit Phusion HotStart High Fidelity Polymerase (Finnzymes,
Woburn, MA, USA). Cycling conditions entailed an initial denaturation
at 98 °C for 30 s followed by 45 cycles of denaturation (98 °C for 10 s),
annealing (60 °C for 75 s) and elongation (72 °C for 30 s), with a final
elongation at 72 °C for 4 min.
PCR products were purified (AMPure, Beckman Coulter, Brea, CA,
USA) and aliquots of 7 μl were used for the sequencing reaction with 1
μM of the universal M13 sequencing primer and 2 μl of GenomeLab
DTCS-Quick Start Kit (Beckman Coulter, Brea, CA, USA) in a final vo-
lume of 10 μl according to the manufacturers protocol. Sequencing
reactions were purified (CleanSEQ, Beckman Coulter, Brea, CA, USA)
and analyzed in a GenomeLab GeXP Genetic Analysis System and
evaluated by the GenomeLab GeXP software 10.2 (Beckman Coulter,
Brea, CA, USA) to determine the mutation status.
2.4. Tumor cell proportion analysis
The proportion of tumor cells was evaluated independently by two
pathologists at the Department of Pathology, University of Tuebingen,
and defined as percentage (%) of tumor cells compared to non tu-
morous cells on fixed tissue specimens. In cases of reduced tumor cell
percentage, microdissection was performed on unstained serial paraffin
sections in order to increase tumor cell percentage and optimize further
analysis.
2.5. Statistical analysis
For statistically analysis SAS jmp® 11.2 (SAS, Cary, United States)
was used. Comparisons between groups were made using the following
tests: age – t-test; localization of tumor and timeline of tumor biopsy in
relation to cancer treatment –Fisher’s exact test; tumor staging, histo-
pathological classification, subcharacterization and comparison of
bronchoscopic techniques – chi-square test; EGFR mutation frequency –
2 × 2 contingency table; tumor cell proportion – t-test. Significance
was defined as p- value<0.05.
3. Results
3.1. Patient characteristics
Demographic data of the cryobiopsy group and the non-cryobiopsy
group were comparable with regard to age and gender, as shown in
Table 1. Almost all patients were Causasian (> 99 %). Due to the ret-
rospective study design smoking status was unknown in a large pro-
portion of patients, but when known, it did not differ between both
groups.
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3.2. Tumor characteristics
Tumor characteristics for both groups are shown in Table 2. Cryo-
biopsy was used more frequently for sampling of central tumors (85.6
%), while non-cryobiopsy techniques were more frequently used in
peripheral tumors (66.1 %). The proportion of advanced cancers
Fig. 1. Study population. n – absolute number; CUP – cancer of unknown primary; Extrapulmonary LN biopsy – extrapulmonary lymph node biopsy; FNAC – fine
needle aspiration cytology.
Table 1
Patient characteristicsa.
Diagnostic procedure Cryobiopsy Non cryobiopsy p-value
Total number of patients, n 125 289 –
Age – year
Median 65 66 n.s.
Sex - no (%)
Male 77 (61.6) 183 (63.3)
Female 48 (38.4) 106 (36.7) n.s.
Smoking status
Known, n (100 %) 69 165
- Never smoker, n (%) 5 (7.2) 13 (7.9) n.s.
- Ever smoker, n (%) 64 (92.8) 152 (92.1)
Unknown 56 124
a Patient characteristics (total number, median age, gender and smoking
status) comparing the cryobiopsy group with the non cryobiopsy group.
Table 2
Tumor characteristicsa.
Diagnostic procedure Cryobiopsy Non
cryobiopsy
p-value
Total number of patients, n (%) 125 (100) 289 (100)
Localisation of tumor, n (%)• Central 107 (85.6) 98 (33.9) < 0.05• Peripheral 18 (14.4) 191(66.1)
Tumor staging, n (%) <0.05• I 3 (2.4) 27 (9.3)• II 3 (2.4) 19 (6.6)• III 14 (11.2) 39 (13.5)• IV 105 (84.0) 204 (70.6)
Histopathological classification, n
(%)
n.s.
• Adenocarcinoma/ Adenosquamous
cell carcinoma
113 (90.4) 264 (91.3)
• Large cell carcinoma 6 (4.8) 14 (4.8)• Squamous cell carcinoma 5 (4.0) 10 (3.5)• Carcinoma (not otherwise specified) 1 (0.8) 1 (0.4)
a Tumor characteristics (total number, localization of tumor, tumor staging
according to UICC and histopathological classification) comparing the cryo-
biopsy group with the non-cryobiopsy group.
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according to the UICC classification [23] was significantly higher in the
cryobiopsy group compared to the non cryobiopsy group. The dis-
tribution of histological tumor types was similar in both groups. Ex-
amples for preserved tumor tissue for bronchoscopic cryobiopsy and
forceps biopsy are shown in Supplementary Fig. S1.
3.3. Frequency of patients with activating EGFR mutations
Among 125 tumor samples obtained by bronchoscopic cryobiopsy,
27 (21.6 %) tumors showed activating mutations in the EGFR gene,
while in the non cryobiopsy group 40 out of 289 (13.8 %) EGFR mu-
tated tumors were identified. This represented a significantly higher
detection rate (p<0.05) for activating EGFR mutation in tumor sam-
ples obtained using bronchoscopic cryobiopsy compared to non-cryo-
biopsy (Table 3). 29 activating EGFR mutations were detected in 27
patients in the cryobiopsy group with two patients harboring mutations
in two EGFR Exons (18 and 20, respectively 19 and 20).
3.4. Subcharacterization/ specification of detected activating EGFR
mutations
In both cryo- and non-cryobiopsy groups subcharacterization of
activating EGFR mutations showed most changes in Exon 19 (cryo-
biopsy: 48.3 %; forceps biopsy 45.2 %) and 21 (cryobiopsy: 27.6 %;
forceps biopsy 38.1 %) (Supplementary Table ST1). Detected altera-
tions were consistent with the known predominant mutations e.g. de-
letion of exon 19 or mutation L858R in exon 21. There was no sig-
nificant difference in the distribution of mutations between the two
groups.
3.5. Frequency of activating EGFR mutations detected in the non cryobiopsy
group
The frequency of activating EGFR mutations detected in the non-
cryobiopsy group using different techniques is shown in Table 4.
3.6. Comparison of bronchoscopic tissue extraction: influence of tumor
localization and biopsy technique
The overall comparison of bronchoscopic tissue extraction with
conventional forceps biopsy (n = 98) and cryobiopsy (n = 125) did not
reveal any significant difference in the detection rate of activating
EGFR mutations (Supplementary Table ST2).
However, cryobiopsy detected significantly more EGFR activating
mutations in central tumours than forceps biopsy (19.6 % versus 6.5 %
p<0.05), whereas in peripheral lung tumors the detection rate, al-
though higher, was similar for both techniques (cryobiopsy (33.3 %)
and forceps biopsy (26.9 %), Supplementary Table ST2).
In those patients diagnosed by bronchoscopic techniques a sig-
nificantly higher proportion of EGFR mutations could be detected in
peripheral tumors compared to central tumors (28.6 % versus 15.7 %,
Supplementary Table ST3).
3.7. Proportion of tumor cells
Proportion of tumor cells of a tissue sample was defined as de-
scribed above. Percentage of tumor cells was not evaluable in 3 patients
in the cryobiopsy group and 35 patients in the non-cryobiopsy group
due to technical problems (17 patients) or those with only cytology
smear specimens (18 patients). Tumor tissue processing by micro-
dissection was performed in 7 patients (5.6 %) after cryobiopsy and 30
Table 3
Frequency of patients with activating EGFR mutationsa.
Diagnostic procedure Cryobiopsy Non cryobiopsy p-value
Total number of patients, n (%) 125 (100) 289 (100)
Total number of patientswith EGFR mutation(s) 27 (21.6) 40 (13.8) < 0.05
Total number of Patients without EGFR mutation(s) 98 (78.4) 249 (86.2)
a Frequency of patients with/ without activating EGFR mutation(s) comparing the cryobiopsy group with the non-cryobiopsy group.
Table 4
Frequency of activating EGFR mutation detected in NSCLC in the non-cryobiopsy group with regard to the applied techniquea.
Absolute number of patients (n) Specimen with mutation (n) Muation detection rate (%)
Total 289 40 13.8
Bronchoscopy 124 20 16.1
Forceps biopsy 98 17 17.3
Fine needle aspiration cytology 26 3 11.5
Imaging guided transthoracic technique 60 9 15.0
Computer tomography guided biopsy 36 4 11.1
Ultrasound guided biopsy 5 0 0
Ultrasound guided pleural fluid aspiration 18 4 22.2
Ultrasound guided pericardial fluid aspiration 1 1 100.0
Surgical techniques 105 11 10.5
Resection of lung tissue via thoracotomy 45 3(5)° 6.7(11.1)b
Biopsy or excision of extrapulmonary metastasis 25 0 0
Diagnostic video assisted thoracic surgery 18 5 27.8
Extrapulmonary lymph node resection 10 3 30.0
Mediastioscopy 7 0 0
a Frequency of activating EGFR mutations comparing bronchoscopic, imaging guided and surgical techniques for tumor tissue sampling in the non-Cryobiopsy
group. Table shows the absolute number of the different techniques and the corresponding absolute number and frequency of detected activating EGFR mutations,
separately for each technique.
b In one patient with surgical resection of lung tissue three activating mutations in Exon 18, 19 and 21 could be detected simultaneously, leading to the increased
number of 5 detectable mutations in 3 patients.
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patients (10.4 %) in the non-cryobiopsy group to enhance tumor cell
proportion, but this did not significantly differ between both groups (p
= 0.09). Supplementary Table ST 4 shows the proportion of tumor cells
in whole sample. Samples with microdissection were excluded for this
analysis. There was a tendency towards higher tumor cell proportion in
cryobiopsy samples (56.7 %) compared to non-cryobiopsy samples
(51.1 %).
The percentage of tumor cells in cryobiopsy samples (56.7 %,
SD±19.6) was significantly higher compared to bronchoscopic forceps
biopsy samples (46.1 %, SD±20.3) (p< 0.05).
There was no difference in the tumor cell percentage in samples
with activating EGFR mutations compared to those without activating
EGFR muations in either cryo- or non-cryobiopsy samples.
3.8. Timeline of tumor biopsy and cancer treatment
As EGFR mutation detection may differ between treatment-naïve
patients or pretreated patients with relapsed or progressive NSCLC we
evaluated whether patients were treatment-naïve or have already had
cancer treatment before biopsy (Supplementary Table ST 5). Most pa-
tients were untreated at time of biopsy (95.2 % in the cryobiopsy co-
hort, 90.3 % in the non-cryobiopsy cohort). There was no significant
difference between both groups (p = 0.12).
4. Discussion
To our knowledge, this is the first analysis to study the influence of
biopsy techniques on the rate of EGFR mutation detection in patients
with NSCLC. Our restrospective analysis indicates that sampling by
bronchoscopic cryobiopsy increased the detection rate of molecular
genetic alterations in NSCLC in comparison to other biopsy techniques
(21.6 % vs 13.8 % (p< 0.05). Thus cryobiopsy might be able to sub-
stantially increase the number of patients who go on to receive targeted
therapy.
EGFR directed TKI therapy is based on acquired genetic alterations
of the EGFR in Exon 18, 19, 20 and 21 as oncogenic drivers. Mutation
detection serves as a predictor for treatment response. It plays a central
role in the choice of treatment for each patient with advanced NSCLC
due to the improvement of progression free survival and even overall
survival under certain circumstances [9–14].
The prevalence of EGFR mutations varies substantially and is af-
fected by ethnicity, age, gender and smoking history. In our study po-
pulation from the surrounding area of Tuebingen in Southern Germany,
with a Caucasian proportion of> 95 %, the EGFR mutation frequency
with 13.8 % in the non cryobiopsy group is in accordance with the
reported frequencies in large studies of predominantely Caucasian po-
pulations in both France and the United States (11–17%) [19,27].
However, the frequency of 21.6 % in the cryobiopsy group exceed the
expected EGFR mutation level despite there being no observed differ-
ence between cryo- and non-cryo biopsy groups in terms of age, his-
topathological classification, smoking status or gender (Table 1). The
medium age of 64 years in our study population is about 5 years lower
than the expected median age at first diagnosis of 69–70 years in
Germany.
The difference in tumor stage noted between the cryobiopsy and
non-cryobiopsy group does not explain the observed differences in
EGFR mutation rate and the higher perentage in the cryobiopsy group
for the following reasons. Firstly, EGFR mutation develops in early
stage malignancy and remains consistently present during further
tumor development. To our knowledge, there are no data proving dif-
ferences in EGFR- mutation rate as a reflection of tumor stage [28,29].
Secondly, driver mutations are usually consistent between primary
tumor and metastasis [18,30]. Therefore, differences in tumor stage –
whether primary tumor or metastasis – cannot serve as a definitive
explanation for the differences in the observed frequencies of EGFR
mutations.
In most cases diagnosis was based on the primary tumor tissue, only
in few cases lymph node or tissue of metastasis was used. However,
according to Yatabe et al. [30], a heterogeneous distribution of EGFR
mutation is extremely rare in lung adenocarcinoma.
The proportion of tumors located in the central airways was higher
in the cryobiopsy group compared to the non-cryobiopsy group. This
may be explained by the utilization of different techniques in different
situations, such as the use of transthoracic biopsy or surgical biopsy for
peripherally located tumors and cryobiopsy for the more readily ac-
cessible central airway tumors.
In the subgroup of bronchoscopically diagnosed tumors EGFR mu-
tation frequency was significantly higher in perpheral compared to
central tumors, independent of the bronchoscopic technique, (forceps
or cryobiopsy) (Supplementary Table ST3). However, the imbalance in
tumor localization, with significantly more central tumors in the cryo-
biopsy groups compared to the non cryobiopsy group, should theore-
tically result in a higher increased EGFR mutation rate detected in the
non-cryobiopsy group, which was not the case (Supplementary Table
ST2). Thus the rate of EGFR mutations detected in the cryobiopsy group
may be an underestimate of the detection rate if there had been an
equal proportion of central to peripheral tumours in both groups.
The biopsy technique used is influenced by the accessibility of the
neoplastic tissue. In the past there has been little attention paid to tissue
quality in deciding which technique should be used. This is partly ex-
plained by the fact that there are no quality criteria for lung tumor
tissue specimens. Adequacy of tissue has been decided on individual
pathologists’s assessments [31] and limitation of tissue is considered
unavoidable with conventional biopsy techniques. Even in large mul-
ticenter trials molecular analysis of tumor tissue is not possible in a
significant proportion of patients – sometimes this proportion is even
not reported. Due to the lack of evidence, guidelines are forced to limit
their requirements for tumor tissue to a recommendation for “sufficient
cancer cell content” and an “adequate DNA quantity and quality”
without precise definition. On the other hand, the importance of good
quality tumor tissue for exact molecular diagnoses has been emphazied
[17] and large specimens are generally recommended [32–37].
Bronchoscopic cryobiopsy directly addresses these requirements,
since the specimens are of large size, of good quality and with fewer
artifacts [15,20,38,39] compared to other biopsy or aspiration techni-
ques. The size, representative nature and quality of tissue preservation
found in cryo-biopsy specimens compared to forceps biopsy specimens
probably explains the improved EGFR detection rate.
Undoubtedly, the continuous development and optimization of di-
agnoses in molecular tumor characterization, with its step from Sanger
sequencing to next generation sequencing, has improved analytic sen-
sitivity and specificity significantly, and allows tumor specimen char-
acterization down to single cell level [32–37]. However, these highly
sensitive methods are not infallible [40–43], and minimal tumor spe-
cimens may be declared to be representative of the entire tumor al-
though they cannot cover the heterogeneity of tumors. Therefore these
methods face limitations in sensitivity, too [44–47] and type of biopsy
is still essential [48]. Reasons for false negative results may be due to an
imbalance of tumor cells and normal tissue, including inflammatory
and stromal cells [41], a low copy number DNA template [49] or DNA
damage with consecutive sequence artifacts due to formalin fixation
[50,51]. Tumor cell enrichment techniques such as laser capture mi-
crodissection may increase tumor cell content and compensate for some
of the limitations of the sample size and quality, but diagnostic in-
accuracy may still not be overcome completely [39,49,52,53]. There-
fore by using highly sensitive detection techniques, harvesting of re-
presentative, and thus large, biopsies is still crucial. Cryobiopsy
specimens provide the “greater amount of material and greater capacity
to enrich the malignant content” as specified by Lindeman et al. in 2013
[17]. Thus increased tumour sample size, with consequentially more
representative material, may be enough to explain the increase in de-
tection of EGFR mutation in cryobiopsy specimens. Arimura et al.
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showed that gene analysis and whole genome sequencing is possible on
cryobiopsy samples and supposed an advantage compared to forceps
biopsy [54,55]. Naito et al. measured a larger amount of DNA in
cryobiopsies compared to forceps biopsies resulting in more successful
whole-exome sequencing. [56].
Liquid biopsy for detection of cell-free tumor DNA and circulating
tumor cells in the blood of advanced NSCLC patients has emerged as a
non-invasive concept in EGFR mutation detection. This may overcome
some of the risks and challenges of solide tissue sampling [57,58].
However, the sensitivity of these sequencing techniques has been re-
ported to reach only 60–80 % as shedding of DNA into the bloodstream
differs from tumor to tumor and from patient to patient [59,60]. This
may explain the false negative rate of liquid biopsy. A clinically re-
levant example is the T790 M resistant mutation. In a case series liquid
biopsy missed the detection of histologically proven mutation in 30 %
of the cases [59,61]. Another limitation is the fact that PD-L1 tumor cell
reactivity analysis can not be performed by using liquid biopsy. Thus
liquid biopsy may serve as additive, sometimes substitutive techniques
for moleculargenetic NSCLC analysis, but has not demonstrated to re-
place solide tissue sampling reliably.
Our study has several limitations. The retrospective approach does
not allow a balance between both study groups, and this has led to an
observed imbalance in tumor staging and localization in the groups.
The type of bronchoscopic biopsy was not defined and the different
techniques (cryobiopsy, forceps biopsy or fine needle aspiration) were
used upon investigators choice. We did not differentiate between first
diagnosis and relapse of disease in either group. However most patients
were treatment-naïve when biopsy was taken (95.2 % in the cryobiopsy
cohort, 90.3 % in the non-cryobiopsy cohort) (Suppementary Table
ST5). As rebiopsy would rather be expected in a certain amount of
known EGFR-mutated patients in order to evaluate for required T790 M
mutation, the higher percentage of pretreated patients would rather
favor a higher percentage of detectable EGFR muations in the non-
cryobiopsy cohort.
We used Sanger sequencing as the former gold standard for EGFR
mutation analysis in all cases, though nowadays it has been replaced
stepwise by next generation sequencing or other techniques providing
an increase in sensitivity. This could have resulted in missing some of
the EGFR mutations. It has to be noted, that this less sensitive analyzing
technique was used for both cohorts. However it cannot be concluded,
that a more sensitive analyzing technique would have canceled out the
differences.
The EGFR mutations rate in the non-cryobiopsy cohort was 13.8 %
and thus even higher than previously reported 9.8 % and 10.3 % for a
Caucasian European NSCLC cohort in Germany [62,63].
Interestingly, the largest metaanalysis on EGFR mutation pre-
valence, including 456 studies (only in 2 studies Sanger sequencing was
used), showed an EGFR mutation prevalence of 14.1 % (95 % con-
fidence interval 12.7 %–15.5 %) for the European population which is
comparable to the rate in our study [64].
Due to the retrospective design of the study there was no strict
protocol for indication when a cryobiopsy or another procedure was
performed. Furthermore there were cases in which a cryobiopsy could
not be applied e.g. mediastinal lymph node assessment.
We assume that the observed differences between biopsy techniques
reflect the importance of adequate NSCLC tumor sampling for mole-
cular characterization. Up till now this has only partially been taken
into account or has been neglected completely when trying to optimise
molecular diagnoses. However, correct molecular typing is crucial for
prognosis, therapeutic choice, and quality of life in lung cancer pa-
tients. Any stepwise diagnostics are always limited by the step of least
sensitivity. Therefore each step of the diagnostic pathway has to be
optimized. The current study illustrates that some current biopsy
techniques may be inadequate to reach this goal and even subsequent
applied analytics of highest sensivitiy may not be able to overcome this
problem. We suggest adhering to the current guidelines [17] but we are
aware of the retrospective character of our study and therefore a pro-
spective trial is required to prove our findings. Even a small increase in
mutation detection in NSCLC would have significant implications for
many patients’ lives.
In conclusion, bronchosopic cryobiopsy is feasible for EGFR detec-
tion analysis in NSCLC and increases the detection rate of activating
EGFR mutations in comparison to other tissue sampling techniques.
Therefore it may optimize individualized treatment in a substantial
number of patients and offer additional therapeutic options. However,
due to the retrospective nature of our study, a prospective trial is
mandatory for final assessment.
Authors’ contributions
MH contributed to the concept, performed the bronchoscopic pro-
cedures, analyzed the data, performed statistical analysis and wrote the
main part of the manuscript. MB contributed to the concept and per-
formed the bronchoscopic procedures. AE analyzed the data and con-
tributed to the manuscript. RW analyzed the data and performed sta-
tistical analysis. W.S. performed the bronchoscopic procedures. V.S.
performed the surgical procedures. H.B. and F.F. did the histopatholo-
gical evaluation. MHo performed the guided biopsies and aspirations.
RAL and LK made revisions for the final manuscript.
I.B. performed the molecular genetic tissue analysis. JH conceived
the research concept and strategies, performed the bronchoscopic
procedures, analyzed the data, performed statistical analysis and wrote
the manuscript. All the authors discussed the results and implications,
commented on the manuscript at all stages, and reviewed the final
version prior to submission. All authors read and approved the final
manuscript.
Declaration of Competing Interest
JH has received personal fees from Erbe Elektromedizin GmbH for
workshops and presentations. MH and MB have received personal fees
from Erbe Elektromedizin GmbH for Workshops. AE, RW, WS, VS, HB,
MHo, RAL, FF, LK, IB have no conflict of interest to declare.
Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.lungcan.2019.12.008.
References
[1] R. Siegel, J. Ma, Z. Zou, A. Jemal, Cancer statistics, 2014, CA Cancer J. Clin. 64 (1)
(2014) 9–29.
[2] T.Y. Cheng, S.M. Cramb, P.D. Baade, D.R. Youlden, C. Nwogu, M.E. Reid, The in-
ternational epidemiology of lung cancer: latest trends, disparities, and tumor
characteristics, J. Thorac. Oncol. 11 (10) (2016) 1653–1671.
[3] A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, M.J. Thun, Cancer statistics, 2009, CA
Cancer J. Clin. 59 (4) (2009) 225–249.
[4] D.L. Aisner, C.B. Marshall, Molecular pathology of non-small cell lung cancer: a
practical guide, Am. J. Clin. Pathol. 138 (3) (2012) 332–346.
[5] T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto,
B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis,
D.C. Christiani, J. Settleman, D.A. Haber, Activating mutations in the epidermal
growth factor receptor underlying responsiveness of non-small-cell lung cancer to
gefitinib, N. Engl. J. Med. 350 (21) (2004) 2129–2139.
[6] R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, R. Palmero,
R. Garcia-Gomez, C. Pallares, J.M. Sanchez, R. Porta, M. Cobo, P. Garrido, F. Longo,
T. Moran, A. Insa, F. De Marinis, R. Corre, I. Bover, A. Illiano, E. Dansin, J. de
Castro, M. Milella, N. Reguart, G. Altavilla, U. Jimenez, M. Provencio, M.A. Moreno,
J. Terrasa, J. Munoz-Langa, J. Valdivia, D. Isla, M. Domine, O. Molinier,
J. Mazieres, N. Baize, R. Garcia-Campelo, G. Robinet, D. Rodriguez-Abreu,
G. Lopez-Vivanco, V. Gebbia, L. Ferrera-Delgado, P. Bombaron, R. Bernabe,
A. Bearz, A. Artal, E. Cortesi, C. Rolfo, M. Sanchez-Ronco, A. Drozdowskyj,
C. Queralt, I. de Aguirre, J.L. Ramirez, J.J. Sanchez, M.A. Molina, M. Taron, L. Paz-
Ares, Erlotinib versus standard chemotherapy as first-line treatment for European
patients with advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol. 13
(3) (2012) 239–246.
M. Haentschel, et al. Lung Cancer 141 (2020) 56–63
61
[7] J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman,
F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck,
W.R. Sellers, B.E. Johnson, M. Meyerson, EGFR mutations in lung cancer: correla-
tion with clinical response to gefitinib therapy, Science 304 (5676) (2004)
1497–1500.
[8] R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal, C. Camps, M. Majem,
G. Lopez-Vivanco, D. Isla, M. Provencio, A. Insa, B. Massuti, J.L. Gonzalez-Larriba,
L. Paz-Ares, I. Bover, R. Garcia-Campelo, M.A. Moreno, S. Catot, C. Rolfo,
N. Reguart, R. Palmero, J.M. Sanchez, R. Bastus, C. Mayo, J. Bertran-Alamillo,
M.A. Molina, J.J. Sanchez, M. Taron, Screening for epidermal growth factor re-
ceptor mutations in lung cancer, N. Engl. J. Med. 361 (10) (2009) 958–967.
[9] J.C. Yang, Y.L. Wu, M. Schuler, M. Sebastian, S. Popat, N. Yamamoto, C. Zhou,
C.P. Hu, K. O’Byrne, J. Feng, S. Lu, Y. Huang, S.L. Geater, K.Y. Lee, C.M. Tsai,
V. Gorbunova, V. Hirsh, J. Bennouna, S. Orlov, T. Mok, M. Boyer, W.C. Su, K.H. Lee,
T. Kato, D. Massey, M. Shahidi, V. Zazulina, L.V. Sequist, Afatinib versus cisplatin-
based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung
3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3
trials, Lancet Oncol. 16 (2) (2015) 141–151.
[10] Y.L. Wu, C. Zhou, C.K. Liam, G. Wu, X. Liu, Z. Zhong, S. Lu, Y. Cheng, B. Han,
L. Chen, C. Huang, S. Qin, Y. Zhu, H. Pan, H. Liang, E. Li, G. Jiang, S.H. How,
M.C. Fernando, Y. Zhang, F. Xia, Y. Zuo, First-line erlotinib versus gemcitabine/
cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung
cancer: analyses from the phase III, randomized, open-label, ENSURE study, Ann.
Oncol. 26 (9) (2015) 1883–1889.
[11] C. Zhou, Y.L. Wu, G. Chen, J. Feng, X.Q. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou,
S. Ren, S. Lu, L. Zhang, C. Hu, C. Hu, Y. Luo, L. Chen, M. Ye, J. Huang, X. Zhi,
Y. Zhang, Q. Xiu, J. Ma, L. Zhang, C. You, Erlotinib versus chemotherapy as first-
line treatment for patients with advanced EGFR mutation-positive non-small-cell
lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised,
phase 3 study, Lancet Oncol. 12 (8) (2011) 735–742.
[12] M. Fukuoka, Y.L. Wu, S. Thongprasert, P. Sunpaweravong, S.S. Leong,
V. Sriuranpong, T.Y. Chao, K. Nakagawa, D.T. Chu, N. Saijo, E.L. Duffield,
Y. Rukazenkov, G. Speake, H. Jiang, A.A. Armour, K.F. To, J.C. Yang, T.S. Mok,
Biomarker analyses and final overall survival results from a phase III, randomized,
open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically
selected patients with advanced non-small-cell lung cancer in Asia (IPASS), J. Clin.
Oncol. 29 (21) (2011) 2866–2874.
[13] L.V. Sequist, J.C. Yang, N. Yamamoto, K. O’Byrne, V. Hirsh, T. Mok, S.L. Geater,
S. Orlov, C.M. Tsai, M. Boyer, W.C. Su, J. Bennouna, T. Kato, V. Gorbunova,
K.H. Lee, R. Shah, D. Massey, V. Zazulina, M. Shahidi, M. Schuler, Phase III study of
afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarci-
noma with EGFR mutations, J. Clin. Oncol. 31 (27) (2013) 3327–3334.
[14] J.C. Yang, V. Hirsh, M. Schuler, N. Yamamoto, K.J. O’Byrne, T.S. Mok, V. Zazulina,
M. Shahidi, J. Lungershausen, D. Massey, M. Palmer, L.V. Sequist, Symptom control
and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/peme-
trexed in patients with advanced lung adenocarcinoma with EGFR mutations, J.
Clin. Oncol. 31 (27) (2013) 3342–3350.
[15] L.M. Ofiara, A. Navasakulpong, S. Beaudoin, A.V. Gonzalez, Optimizing tissue
sampling for the diagnosis, subtyping, and molecular analysis of lung cancer, Front.
Oncol. 4 (2014) 253.
[16] J. Dionisio, Diagnostic flexible bronchoscopy and accessory techniques, Rev. Port.
Pneumol. 18 (2) (2012) 99–106.
[17] N.I. Lindeman, P.T. Cagle, M.B. Beasley, D.A. Chitale, S. Dacic, G. Giaccone,
R.B. Jenkins, D.J. Kwiatkowski, J.S. Saldivar, J. Squire, E. Thunnissen, M. Ladanyi,
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK
tyrosine kinase inhibitors: guideline from the College of American Pathologists,
International Association for the Study of Lung Cancer, and Association for
Molecular Pathology, J. Thorac. Oncol. 8 (7) (2013) 823–859.
[18] N.B. Leighl, N. Rekhtman, W.A. Biermann, J. Huang, M. Mino-Kenudson,
S.S. Ramalingam, H. West, S. Whitlock, M.R. Somerfield, Molecular testing for se-
lection of patients with lung cancer for epidermal growth factor receptor and
anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical
Oncology endorsement of the College of American Pathologists/International
Association for the study of lung cancer/association for molecular pathology
guideline, J. Clin. Oncol. 32 (32) (2014) 3673–3679.
[19] M.G. Kris, B.E. Johnson, L.D. Berry, D.J. Kwiatkowski, A.J. Iafrate, I.I. Wistuba,
M. Varella-Garcia, W.A. Franklin, S.L. Aronson, P.F. Su, Y. Shyr, D.R. Camidge,
L.V. Sequist, B.S. Glisson, F.R. Khuri, E.B. Garon, W. Pao, C. Rudin, J. Schiller,
E.B. Haura, M. Socinski, K. Shirai, H. Chen, G. Giaccone, M. Ladanyi, K. Kugler,
J.D. Minna, P.A. Bunn, Using multiplexed assays of oncogenic drivers in lung
cancers to select targeted drugs, Jama 311 (19) (2014) 1998–2006.
[20] J. Hetzel, R. Eberhardt, F.J. Herth, C. Petermann, G. Reichle, L. Freitag,
I. Dobbertin, K.J. Franke, F. Stanzel, T. Beyer, P. Moller, P. Fritz, G. Ott,
P.A. Schnabel, H. Kastendieck, W. Lang, A.T. Morresi-Hauf, M.N. Szyrach,
R. Muche, P.L. Shah, A. Babiak, M. Hetzel, Cryobiopsy increases the diagnostic yield
of endobronchial biopsy: a multicentre trial, Eur. Respir. J. 39 (3) (2012) 685–690.
[21] J. Hetzel, M. Hetzel, C. Hasel, P. Moeller, A. Babiak, Old meets modern: the use of
traditional cryoprobes in the age of molecular biology, Respiration 76 (2) (2008)
193–197.
[22] F. Sanger, S. Nicklen, A.R. Coulson, DNA sequencing with chain-terminating in-
hibitors, Proc. Natl. Acad. Sci. U. S. A. 74 (12) (1977) 5463–5467.
[23] S. Mirsadraee, D. Oswal, Y. Alizadeh, A. Caulo, E. van Beek Jr., The 7th lung cancer
TNM classification and staging system: review of the changes and implications,
World J. Radiol. 4 (4) (2012) 128–134.
[24] K. Sotlar, L. Escribano, O. Landt, S. Mohrle, S. Herrero, A. Torrelo, U. Lass,
H.P. Horny, B. Bultmann, One-step detection of c-kit point mutations using peptide
nucleic acid-mediated polymerase chain reaction clamping and hybridization
probes, Am. J. Pathol. 162 (3) (2003) 737–746.
[25] D.H. Lee, G.K. Lee, S.Y. Kong, M.C. Kook, S.K. Yang, S.Y. Park, S.H. Park, B. Keam,
D.J. Park, B.Y. Cho, S.W. Kim, K.W. Chung, E.S. Lee, S.W. Kim, Epidermal growth
factor receptor status in anaplastic thyroid carcinoma, J. Clin. Pathol. 60 (8) (2007)
881–884.
[26] M. Yang, B. Shan, Q. Li, X. Song, J. Cai, J. Deng, L. Zhang, Z. Du, J. Lu, T. Chen,
J.P. Wery, Y. Chen, Q. Li, Overcoming erlotinib resistance with tailored treatment
regimen in patient-derived xenografts from naive Asian NSCLC patients, Int. J.
Cancer 132 (2) (2013) E74–84.
[27] F. Barlesi, J. Mazieres, J.P. Merlio, D. Debieuvre, J. Mosser, H. Lena, L. Ouafik,
B. Besse, I. Rouquette, V. Westeel, F. Escande, I. Monnet, A. Lemoine, R. Veillon,
H. Blons, C. Audigier-Valette, P.P. Bringuier, R. Lamy, M. Beau-Faller, J.L. Pujol,
J.C. Sabourin, F. Penault-Llorca, M.G. Denis, S. Lantuejoul, F. Morin, Q. Tran,
P. Missy, A. Langlais, B. Milleron, J. Cadranel, J.C. Soria, G. Zalcman, Routine
molecular profiling of patients with advanced non-small-cell lung cancer: results of
a 1-year nationwide programme of the French Cooperative Thoracic Intergroup
(IFCT), Lancet (London, England) 387 (10026) (2016) 1415–1426.
[28] E.C. de Bruin, C. Cowell, P.H. Warne, M. Jiang, R.E. Saunders, M.A. Melnick,
S. Gettinger, Z. Walther, A. Wurtz, G.J. Heynen, D.A. Heideman, J. Gomez-Roman,
A. Garcia-Castano, Y. Gong, M. Ladanyi, H. Varmus, R. Bernards, E.F. Smit, K. Politi,
J. Downward, Reduced NF1 expression confers resistance to EGFR inhibition in
lung cancer, Cancer Discov. 4 (5) (2014) 606–619.
[29] Z. Zhang, A.L. Stiegler, T.J. Boggon, S. Kobayashi, B. Halmos, EGFR-mutated lung
cancer: a paradigm of molecular oncology, Oncotarget 1 (7) (2010) 497–514.
[30] Y. Yatabe, K. Matsuo, T. Mitsudomi, Heterogeneous distribution of EGFR mutations
is extremely rare in lung adenocarcinoma, J. Clin. Oncol. 29 (22) (2011)
2972–2977.
[31] M.S. Tsao, A. Sakurada, J.C. Cutz, C.Q. Zhu, S. Kamel-Reid, J. Squire, I. Lorimer,
T. Zhang, N. Liu, M. Daneshmand, P. Marrano, G. da Cunha Santos, A. Lagarde,
F. Richardson, L. Seymour, M. Whitehead, K. Ding, J. Pater, F.A. Shepherd,
Erlotinib in lung cancer - molecular and clinical predictors of outcome, N. Engl. J.
Med. 353 (2) (2005) 133–144.
[32] S. Billah, J. Stewart, G. Staerkel, S. Chen, Y. Gong, M. Guo, EGFR and KRAS mu-
tations in lung carcinoma: molecular testing by using cytology specimens, Cancer
Cytopathol. 119 (2) (2011) 111–117.
[33] C.M. Chen, J.W. Chang, Y.C. Cheung, G. Lin, J.J. Hsieh, T. Hsu, S.F. Huang,
Computed tomography-guided core-needle biopsy specimens demonstrate epi-
dermal growth factor receptor mutations in patients with non-small-cell lung
cancer, Acta Radiol. (Stockholm, Sweden: 1987) 49 (9) (2008) 991–994.
[34] L. Boldrini, S. Gisfredi, S. Ursino, T. Camacci, E. Baldini, F. Melfi, G. Fontanini,
Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a
sensitive method for molecular diagnosis, J. Thorac. Oncol. 2 (12) (2007)
1086–1090.
[35] A. Fassina, A. Gazziero, D. Zardo, M. Corradin, E. Aldighieri, G.P. Rossi, Detection
of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by
high resolution melting analysis, J. Clin. Pathol. 62 (12) (2009) 1096–1102.
[36] J.H. Smouse, E.S. Cibas, P.A. Janne, V.A. Joshi, K.H. Zou, N.I. Lindeman, EGFR
mutations are detected comparably in cytologic and surgical pathology specimens
of nonsmall cell lung cancer, Cancer 117 (1) (2009) 67–72.
[37] M.D. Lozano, J.J. Zulueta, J.I. Echeveste, A. Gurpide, L.M. Seijo, S. Martin-Algarra,
A. Del Barrio, R. Pio, M.A. Idoate, T. Labiano, J.L. Perez-Gracia, Assessment of
epidermal growth factor receptor and K-ras mutation status in cytological stained
smears of non-small cell lung cancer patients: correlation with clinical outcomes,
Oncologist 16 (6) (2011) 877–885.
[38] S. Griff, W. Ammenwerth, N. Schonfeld, T.T. Bauer, T. Mairinger, T.G. Blum,
J. Kollmeier, W. Gruning, Morphometrical analysis of transbronchial cryobiopsies,
Diagn. Pathol. 6 (2011) 53.
[39] S. Querings, J. Altmuller, S. Ansen, T. Zander, D. Seidel, F. Gabler, M. Peifer,
E. Markert, K. Stemshorn, B. Timmermann, B. Saal, S. Klose, K. Ernestus,
M. Scheffler, W. Engel-Riedel, E. Stoelben, E. Brambilla, J. Wolf, P. Nurnberg,
R.K. Thomas, Benchmarking of mutation diagnostics in clinical lung cancer speci-
mens, PLoS One 6 (5) (2011) e19601.
[40] A. Marchetti, C. Martella, L. Felicioni, F. Barassi, S. Salvatore, A. Chella,
P.P. Camplese, T. Iarussi, F. Mucilli, A. Mezzetti, F. Cuccurullo, R. Sacco, F. Buttitta,
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and
development of a rapid and sensitive method for diagnostic screening with potential
implications on pharmacologic treatment, J. Clin. Oncol. 23 (4) (2005) 857–865.
[41] P.A. Janne, A.M. Borras, Y. Kuang, A.M. Rogers, V.A. Joshi, H. Liyanage,
N. Lindeman, J.C. Lee, B. Halmos, E.A. Maher, R.J. Distel, M. Meyerson,
B.E. Johnson, A rapid and sensitive enzymatic method for epidermal growth factor
receptor mutation screening, Clin. Cancer Res. 12 (3 Pt 1) (2006) 751–758.
[42] Q. Pan, W. Pao, M. Ladanyi, Rapid polymerase chain reaction-based detection of
epidermal growth factor receptor gene mutations in lung adenocarcinomas, J. Mol.
Diagn. 7 (3) (2005) 396–403.
[43] H. Sasaki, K. Endo, A. Konishi, M. Takada, M. Kawahara, K. Iuchi, A. Matsumura,
M. Okumura, H. Tanaka, T. Kawaguchi, T. Shimizu, H. Takeuchi, M. Yano, I. Fukai,
Y. Fujii, EGFR Mutation status in Japanese lung cancer patients: genotyping ana-
lysis using LightCycler, Clin. Cancer Res. 11 (8) (2005) 2924–2929.
[44] K. Endo, A. Konishi, H. Sasaki, M. Takada, H. Tanaka, M. Okumura, M. Kawahara,
H. Sugiura, Y. Kuwabara, I. Fukai, A. Matsumura, M. Yano, Y. Kobayashi,
K. Mizuno, H. Haneda, E. Suzuki, K. Iuchi, Y. Fujii, Epidermal growth factor re-
ceptor gene mutation in non-small cell lung cancer using highly sensitive and fast
TaqMan PCR assay, Lung Cancer (Amsterdam, Netherlands) 50 (3) (2005) 375–384.
[45] K. Hoshi, H. Takakura, Y. Mitani, K. Tatsumi, N. Momiyama, Y. Ichikawa, S. Togo,
T. Miyagi, Y. Kawai, Y. Kogo, T. Kikuchi, C. Kato, T. Arakawa, S. Uno, P.E. Cizdziel,
M. Haentschel, et al. Lung Cancer 141 (2020) 56–63
62
A. Lezhava, N. Ogawa, Y. Hayashizaki, H. Shimada, Rapid detection of epidermal
growth factor receptor mutations in lung cancer by the SMart-amplification process,
Clin. Cancer Res. 13 (17) (2007) 4974–4983.
[46] D.A. Heideman, F.B. Thunnissen, M. Doeleman, D. Kramer, H.M. Verheul, E.F. Smit,
P.E. Postmus, C.J. Meijer, G.A. Meijer, P.J. Snijders, A panel of high resolution
melting (HRM) technology-based assays with direct sequencing possibility for ef-
fective mutation screening of EGFR and K-ras genes, Cell. Oncol. 31 (5) (2009)
329–333.
[47] H. Miyazawa, T. Tanaka, Y. Nagai, M. Matsuoka, A. Sutani, K. Udagawa, J. Zhang,
T. Hirama, Y. Murayama, N. Koyama, K. Ikebuchi, M. Nagata, M. Kanazawa,
T. Nukiwa, S. Takenoshita, K. Kobayashi, K. Hagiwara, Peptide nucleic acid-locked
nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-re-
fractory T790M epidermal growth factor receptor mutation, Cancer Sci. 99 (3)
(2008) 595–600.
[48] I.S. Hagemann, S. Devarakonda, C.M. Lockwood, D.H. Spencer, K. Guebert,
A.J. Bredemeyer, H. Al-Kateb, T.T. Nguyen, E.J. Duncavage, C.E. Cottrell,
S. Kulkarni, R. Nagarajan, K. Seibert, M. Baggstrom, S.N. Waqar, J.D. Pfeifer,
D. Morgensztern, R. Govindan, Clinical next-generation sequencing in patients with
non-small cell lung cancer, Cancer 121 (4) (2015) 631–639.
[49] M. Akbari, M.D. Hansen, J. Halgunset, F. Skorpen, H.E. Krokan, Low copy number
DNA template can render polymerase chain reaction error prone in a sequence-
dependent manner, J. Mol. Diagn. 7 (1) (2005) 36–39.
[50] C. Wong, R.A. DiCioccio, H.J. Allen, B.A. Werness, M.S. Piver, Mutations in BRCA1
from fixed, paraffin-embedded tissue can be artifacts of preservation, Cancer Genet.
Cytogenet. 107 (1) (1998) 21–27.
[51] C. Williams, F. Ponten, C. Moberg, P. Soderkvist, M. Uhlen, J. Ponten, G. Sitbon,
J. Lundeberg, A high frequency of sequence alterations is due to formalin fixation of
archival specimens, Am. J. Pathol. 155 (5) (1999) 1467–1471.
[52] D.A. Eberhard, G. Giaccone, B.E. Johnson, Biomarkers of response to epidermal
growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group:
standardization for use in the clinical trial setting, J. Clin. Oncol. 26 (6) (2008)
983–994.
[53] N.L. Sieben, N.T. ter Haar, C.J. Cornelisse, G.J. Fleuren, A.M. Cleton-Jansen, PCR
artifacts in LOH and MSI analysis of microdissected tumor cells, Hum. Pathol. 31
(11) (2000) 1414–1419.
[54] K. Arimura, M. Kondo, Y. Nagashima, M. Kanzaki, F. Kobayashi, K. Takeyama,
J. Tamaoki, E. Tagaya, Comparison of tumor cell numbers and 22C3 PD-L1 ex-
pression between cryobiopsy and transbronchial biopsy with endobronchial ultra-
sonography-guide sheath for lung cancer, Respir. Res. 20 (1) (2019) 185.
[55] K. Arimura, E. Tagaya, H. Akagawa, Y. Nagashima, S. Shimizu, Y. Atsumi, A. Sato,
M. Kanzaki, M. Kondo, K. Takeyama, P.P. Massion, J. Tamaoki, Cryobiopsy with
endobronchial ultrasonography using a guide sheath for peripheral pulmonary le-
sions and DNA analysis by next generation sequencing and rapid on-site evaluation,
Respir. Investig. 57 (2) (2019) 150–156.
[56] T. Naito, H. Udagawa, K. Kirita, T. Ikeda, Y. Zenke, S. Matsumoto, K. Yoh, S. Niho,
G. Ishii, K. Goto, D.A. Haber, V.E. Velculescu, Blood-based analyses of cancer:
circulating tumor cells and circulating tumor DNA, Cancer Discov. 4 (6) (2014)
650–661.
[57] D.A. Haber, V.E. Velculescu, Blood-based analyses of cancer: circulating tumor cells
and circulating tumor DNA, Cancer Discov. 4 (6) (2014) 650–661.
[58] Y.L. Wu, L.V. Sequist, C.P. Hu, J. Feng, S. Lu, Y. Huang, W. Li, M. Hou, M. Schuler,
T. Mok, N. Yamamoto, K. O’Byrne, V. Hirsh, N. Gibson, D. Massey, M. Kim,
J.C. Yang, EGFR mutation detection in circulating cell-free DNA of lung adeno-
carcinoma patients: analysis of LUX-Lung 3 and 6, Br. J. Cancer 116 (2) (2017)
175–185.
[59] G.R. Oxnard, K.S. Thress, R.S. Alden, R. Lawrance, C.P. Paweletz, M. Cantarini,
J.C. Yang, J.C. Barrett, P.A. Janne, Association between plasma genotyping and
outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung
cancer, J. Clin. Oncol. 34 (28) (2016) 3375–3382.
[60] A.G. Sacher, C. Paweletz, S.E. Dahlberg, R.S. Alden, A. O’Connell, N. Feeney,
S.L. Mach, P.A. Janne, G.R. Oxnard, Prospective validation of rapid plasma geno-
typing for the detection of EGFR and KRAS mutations in advanced lung cancer,
JAMA Oncol. 2 (8) (2016) 1014–1022.
[61] J.D. Merker, G.R. Oxnard, C. Compton, M. Diehn, P. Hurley, A.J. Lazar,
N. Lindeman, C.M. Lockwood, A.J. Rai, R.L. Schilsky, A.M. Tsimberidou, P. Vasalos,
B.L. Billman, T.K. Oliver, S.S. Bruinooge, D.F. Hayes, N.C. Turner, Circulating tumor
DNA analysis in patients with cancer: American Society of Clinical Oncology and
College of American Pathologists Joint Review, J. Clin. Oncol. 36 (16) (2018)
1631–1641.
[62] S. Gahr, R. Stoehr, E. Geissinger, J.H. Ficker, W.M. Brueckl, A. Gschwendtner,
S. Gattenloehner, F.S. Fuchs, C. Schulz, R.J. Rieker, A. Hartmann, P. Ruemmele,
W. Dietmaier, EGFR mutational status in a large series of Caucasian European
NSCLC patients: data from daily practice, Br. J. Cancer 109 (7) (2013) 1821–1828.
[63] W. Schuette, P. Schirmacher, W.E. Eberhardt, J.R. Fischer, J.M. von der
Schulenburg, J. Mezger, C. Schumann, M. Serke, S. Zaun, M. Dietel, M. Thomas,
EGFR mutation status and first-line treatment in patients with stage III/IV non-small
cell lung cancer in Germany: an observational study, Cancer Epidemiol. Biomarkers
Prev. 24 (8) (2015) 1254–1261.
[64] Y.L. Zhang, J.Q. Yuan, K.F. Wang, X.H. Fu, X.R. Han, D. Threapleton, Z.Y. Yang,
C. Mao, J.L. Tang, The prevalence of EGFR mutation in patients with non-small cell
lung cancer: a systematic review and meta-analysis, Oncotarget 7 (48) (2016)
78985–78993.
M. Haentschel, et al. Lung Cancer 141 (2020) 56–63
63
